Sign In
Buy BNTX
$89.59
+1.14 (+1.29%)
At Close: Jun 04, 2026
BioNTech Earnings and Sales Top Wall Street Forecasts
06:05am, Monday, 09'th May 2022
BioNTech earns €14.24 a share in the first quarter on revenue of €6.37 billion.
Palantir, Plug Power, Novavax, BioNTech, Lordstown: 5 Key Earnings To Watch Today
05:23am, Monday, 09'th May 2022
The first-quarter reporting season is well and truly underway. Data from Factset show that about 87% of S&P 500 companies have reported their quarterly results, with 79% reporting positive earning
Disney, Occidental, Rivian, Palantir, BioNTech, and Other Stocks to Watch This Week
03:00pm, Sunday, 08'th May 2022
First quarter earnings reports this week include BioNTech, Palantir, Simon Property Group, Tyson Foods, Electronic Arts, Occidental Petroleum, and Walt Disney. Plus, inflation data.
Why BioNTech Stock Crushed the Market Today
04:41pm, Monday, 02'nd May 2022
The company launches a two-year share buyback program.
Top Pharmaceutical Stocks To Watch In May 2022
09:45am, Saturday, 30'th Apr 2022
Check out these pharmaceutical stocks in the stock market today.
Thinking of Buying BioNTech? Consider These 3 Things First
10:45am, Friday, 29'th Apr 2022
There's trouble ahead, but a few new solutions are on the way too.
BioNTech, Pfizer say they expect to have COVID-19 vaccine data for young children this quarter
10:28am, Wednesday, 27'th Apr 2022
BioNTech SE BNTX, -2.86% and Pfizer Inc. PFE, -0.42% said Tuesday that they expect to share data from a clinical trial evaluating their COVID-19 vaccines in children between the ages of 6 months and 5
BioNTech, Pfizer seek FDA authorization of a COVID-19 booster for young children
10:15am, Wednesday, 27'th Apr 2022
BioNTech SE BNTX, -2.24% and Pfizer Inc. PFE, -0.17% said Tuesday that they asked the Food and Drug Administration to authorize a COVID-19 booster dose for children between the ages of 5 and 11 years
BioNTech to Report First Quarter 2022 Financial Results and Operational Update on May 9, 2022
07:00am, Tuesday, 26'th Apr 2022
Mainz, Germany, April 26, 2022 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2022 on Monday, May 9th, 2
Why BioNTech SE Was Surging Today
04:45pm, Monday, 25'th Apr 2022
The vaccine maker got a dose of good news late last week, and ongoing lockdowns in China perhaps spurred some optimism.
What's Happening With BioNTech SE Shares?
03:27pm, Monday, 25'th Apr 2022
Shares of vaccine companies, including BioNTech SE - ADR (NASDAQ: BNTX), are trading higher amid COVID-19 concerns due to rising cases in China. Rising COVID-19 cases in China's capital Beijing and Sh
BioNTech SE Sponsored ADR (BNTX) Stock Moves -1.87%: What You Should Know
09:50pm, Friday, 22'nd Apr 2022 Zacks Investment Research
BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $145.07, moving -1.87% from the previous trading session.
Does This Vaccine-Maker's Upcoming Share Repurchase Make It a Buy?
02:07pm, Friday, 22'nd Apr 2022 The Motley Fool
It could be an important sign of a transitional period to come.
Does This Vaccine-Maker's Upcoming Share Repurchase Make It a Buy?
10:07am, Friday, 22'nd Apr 2022
It could be an important sign of a transitional period to come.
Novavax (NVAX) Posts Upbeat Data on COVID/Flu Combo Jab Study
03:58pm, Thursday, 21'st Apr 2022 Zacks Investment Research
Results from Novavax's (NVAX) phase I/II study, which is evaluating a combination of its COVID-19 vaccine and the seasonal influenza vaccine candidate, demonstrate the combo vaccine's feasibility.
